Which has the lower trailing P/E, BMRN or ENSG?

ENSG has the lower trailing P/E: BMRN trades at 147.54 and ENSG at 27.10. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, BMRN or ENSG?

Over the past five years, ENSG grew revenue faster — BMRN at a 12.19% CAGR versus ENSG at 17.08%.

Does BMRN or ENSG pay a bigger dividend?

ENSG pays a dividend (0.15% yield), while BMRN has no payments in the available dividend history.

Is BMRN or ENSG more profitable?

ENSG runs the higher net margin — BMRN at 2.14% versus ENSG at 6.90%.

How have BMRN and ENSG total returns compared?

Over the past 10 years, BMRN delivered -4.98% and ENSG delivered 25.09% annualized total return. Past performance doesn't predict future results.

BioMarin Pharmaceutical Inc. (BMRN) vs The Ensign Group, Inc. (ENSG)

A side-by-side comparison of BioMarin Pharmaceutical Inc. and The Ensign Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BMRN

BioMarin Pharmaceutical Inc.

$11.12B

$57.54HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

ENSG

The Ensign Group, Inc.

$10.08B

$172.89HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — BMRN vs ENSG

growth of $100 · dividends reinvested · last 10y

BMRN -39.5% (-4.9%/yr)ENSG +860.7% (+25.4%/yr)ENSG compounded faster over this window

Log scale — wide-divergence pair

BMRN ENSG

BMRN vs ENSG: by the numbers

•BMRN is the larger company ($11.12B vs $10.08B market cap).
•ENSG trades at the lower trailing earnings multiple (27.10 vs 147.54 P/E), one valuation lens rather than an overall verdict.
•ENSG converts more revenue to profit (6.90% vs 2.14% net margin).
•ENSG grew revenue faster over the past five years (17.08% vs 12.19% CAGR).
•ENSG pays a dividend (0.15% yield), while BMRN has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	BMRN	ENSG
P/E ratio	147.54	27.10
Forward P/E	N/A	22.18
PEG ratio	N/A	1.96
P/S ratio	3.26	1.84
P/B ratio	1.76	4.13
EV / EBITDA	33.90	20.73
FCF yield	6.59%	4.16%

Profitability

Metric	BMRN	ENSG
Gross margin	75.55%	14.14%
Operating margin	16.56%	8.52%
Net margin	2.14%	6.90%
ROE	1.15%	15.51%
ROIC	1.40%	7.29%

Dividends

Metric	BMRN	ENSG
Dividend yield	N/A	0.15%
Payout ratio	N/A	4.04%

Growth (annualized)

Metric	BMRN	ENSG
Revenue CAGR (5Y)	12.19%	17.08%
EPS CAGR (5Y)	-17.46%	13.47%
FCF CAGR (5Y)	33.84%	10.84%
Total return CAGR (5Y)	-5.59%	18.33%

Frequently asked

Which has the lower trailing P/E, BMRN or ENSG?: ENSG has the lower trailing P/E: BMRN trades at 147.54 and ENSG at 27.10. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, BMRN or ENSG?: Over the past five years, ENSG grew revenue faster — BMRN at a 12.19% CAGR versus ENSG at 17.08%.
Does BMRN or ENSG pay a bigger dividend?: ENSG pays a dividend (0.15% yield), while BMRN has no payments in the available dividend history.
Is BMRN or ENSG more profitable?: ENSG runs the higher net margin — BMRN at 2.14% versus ENSG at 6.90%.
How have BMRN and ENSG total returns compared?: Over the past 10 years, BMRN delivered -4.98% and ENSG delivered 25.09% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BMRN analysis Full ENSG analysis Interactive comparison tool

Dig into the metrics

BioMarin Pharmaceutical P/E ratio Ensign P/E ratio Ensign dividend yield BioMarin Pharmaceutical ROE Ensign ROE BioMarin Pharmaceutical operating margin Ensign operating margin BioMarin Pharmaceutical revenue growth Ensign revenue growth BioMarin Pharmaceutical free cash flow Ensign free cash flow

BioMarin Pharmaceutical & Ensign appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.